Phase 3 4WARD trial in chronic neutropenia now activated at ~90% of targeted trial sites; full enrollment expected in 3Q or 4Q 2025; top-line ...

MS patients may receive less frequent rituximab infusions without increasing their chances of relapse or disease progression, ...

After lots of controversy regarding the conduction of the exam, the National Eligibility-Entrance Test Super Speciality (NEET ...

The National Eligibility-Entrance Test Super Speciality (NEET-SS) 2024 finally took place on March 29-30, 2025, following ...

Indivior, leader in opioid treatment, trades near 52-week lows. Read more on INDV stock's financials, growth challenges, and ...

The following is a summary of “Acute neuromyelitis optica spectrum disorder patients’ clinical analysis of disability-related ...

Q4 2024 Earnings Call Transcript March 25, 2025 X4 Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0 ...

AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization to RINVOQ� (upadacitinib; 15 mg, once daily) for the treatment of giant cell arteritis (GCA) in ...

Immunosuppressive therapy improves pancytopenia in severe aplastic anemia.However, its effects are not long-lasting as evidenced by a modest 2-year EFS rate of just 46%, prompting the need for ...

X4 Pharmaceuticals Inc (XFOR) navigates a challenging landscape with strategic cost reductions and promising product developments, despite facing regulatory and market hurdles.